A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing ...

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...